Potentiation of regulatory volume decrease by P2U purinoceptors in HSG-PA cells.
HSG-PA human salivary gland duct cells exhibit progressively increased regulatory volume decrease (RVD) in response to decreased medium osmolarity. The P2U purinoceptor agonist UTP causes a potentiation of RVD, the extent of which is most pronounced in 220 mosM medium and is least apparent in 180 mosM medium. We examined the underlying mechanisms for this effect. Exposure of HSG-PA cells to UTP promotes Ca2+ mobilization, hyperpolarization, and net K+ efflux, suggesting the participation of Ca(2+)-activated K+ channels in RVD. To delineate the anion counterpart of K+ movement during RVD, cell swelling in the presence of gramicidin, which abolishes the membrane potential, was measured. In response to a sudden dilution in hypotonic media, gramicidin-treated cells swelled immediately, followed by a "secondary swelling" in 180 but not in 220 mosM medium. The results suggest that in 180 mosM cells perform spontaneous RVD mediated by increased anion conductance. In 220 mosM medium in which RVD is minimal, the increase in anion conductance is marginal. In our model of RVD in which cells were challenged by UTP, the ensuing hyperpolarization provides the driving force for net Cl- efflux, which is confirmed by tracer flux studies during purinoceptor-activated RVD. Thus RVD, which has long been regarded as a self-sufficient cellular program, appears to be subject to extracellular control in HSG-PA cells through receptor-mediated processes.
Kim
H D
HD
Department of Pharmacology, School of Medicine, University of Missouri, Columbia 65212, USA.
Bowen
J W
JW
James-Kracke
M R
MR
Landon
L A
LA
Camden
J M
JM
Burnett
J E
JE
Turner
J T
JT
D001692:Biological Transport / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D002460:Cell Line; D018999:Charybdotoxin / Q000494:pharmacology; D002712:Chlorides / Q000378:metabolism; D006096:Gramicidin / Q000494:pharmacology; D006801:Humans; D007038:Hypotonic Solutions / Q000494:pharmacology; D007425:Intracellular Membranes / Q000378:metabolism; D007477:Ions; D008564:Membrane Potentials / Q000187:drug effects; D009994:Osmolar Concentration; D015221:Potassium Channels / Q000502:physiology; D011983:Receptors, Purinergic / Q000502:physiology*; D012413:Rubidium / Q000493:pharmacokinetics; D013363:Submandibular Gland / Q000166:cytology* / Q000502:physiology; D014544:Uridine Triphosphate / Q000494:pharmacology
D002712:Chlorides; D007038:Hypotonic Solutions; D007477:Ions; D015221:Potassium Channels; D011983:Receptors, Purinergic; D018999:Charybdotoxin; D006096:Gramicidin; D012413:Rubidium; D002118:Calcium; D014544:Uridine Triphosphate